Navigation Links
MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial Of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion
Date:7/22/2013

TUSTIN, Calif., July 22, 2013 /PRNewswire/ -- MicroVention, Inc., a wholly owned subsidiary of Terumo Corporation, announced earlier last week that they successfully completed their first enrollment in a multi-center, prospective, pivotal U.S. clinical trial to demonstrate the safety and efficacy of its FRED™ flow diversion system (FRED™-Flow Re-Direction Endoluminal Device) for treating intracranial aneurysms. Intracranial aneurysms are an abnormal, outward bulging of an artery in the brain caused by weakness in the arterial wall.

The FRED™ system is currently approved (CE marked) in European countries and several other international markets, where clinical cases have already been performed.

The first patient was enrolled by Aquilla S. Turk, D.O., Director of Neurointerventional Division and Principal Investigator at the Medical University of South Carolina, who commented, "The FRED™ system was successfully deployed to treat a recurrent ophthalmic artery aneurysm that had previously been treated with embolic coils, and the flow diverter device provided the best option for long-term treatment durability.  The FRED™ system was easy to deliver and we believe it represents a step forward in flow diversion stent technology."

Cameron McDougall, M.D., FRCSC, Chief, Endovascular Neurosurgery at the Barrow Neurological Institute in Phoenix, Arizona and Primary Investigator for the multicenter U.S. study commented, "I am very pleased to see the FRED™ system trial officially underway.  I want to thank Dr. Turk and his staff at MUSC for their excellent work in successfully treating our first patient.  I would also like to acknowledge the MicroVention team for all they have done to get us to this point.  It is exciting to see this study move forward, understanding that we have a chance to provide patients with improved treatment options."

Richard Cappetta, President and CEO of MicroVention, Inc. noted that, "The FRED™ system study is intended to provide clinical evidence that MicroVention's next-generation flow diverter device can effectively treat these difficult aneurysms, and offer new endovascular treatment options for physicians. The enhanced visibility and ease of delivery and deployment, key features of the FRED™ system device, will hopefully result in improved clinical outcomes."

A description of this clinical trial can be found at http://clinicaltrials.gov; Study Number: NCT01801007, as required by U.S. Law.

About the FRED™ system
The Flow Re-Direction Endoluminal Device (FRED) system is the next generation flow diversion device intended for the treatment of intracranial aneurysms.  The FRED™ system is an innovative, uniquely paired, integrated dual-layer (stent-within-a-stent) self-expanding nitinol braided design, which is simultaneously deployed by a single operator through a .027 (0.69 mm) inner diameter Headway™ 27 microcatheter.  The higher radial force outer stent, along with the low porosity-high metal surface area inner stent, unite to provide superb ease of use, enhanced stent opening, improved vessel apposition and fluoroscopic visibility, to help reduce and redirect blood flow into the aneurysm sac.  The FRED™ system offers additional benefits over first generation flow diversion devices, by its ability to be partially deployed, retrieved and accurately repositioned/redeployed, without the need for a torque device. 

About MicroVention, Inc.
MicroVention, Inc. is a U.S. subsidiary of Terumo Corporation with its corporate headquarters in Tustin, California, and manufacturing and administrative facilities in Santa Ana and Aliso Viejo, California, and San Jose, Costa Rica.  MicroVention is a developer, manufacturer and marketer of innovative neuroendovascular technologies for the treatment of vascular diseases in small vessels.  MicroVention products are sold throughout the world in more than 62 countries.  For more information, visit www.microvention.com.

About Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations.  Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.  Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve.  Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Media Contact:
Cathy Demyanovich
Director, Corporate Communications
MicroVention. Inc.
800-990-8361
714-247-8000


'/>"/>
SOURCE MicroVention, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroVentions New Manufacturing Plant Facility In Costa Rica Celebrates Grand Opening With Inaugural Plant Ceremony
2. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
3. Kinex Announces that the US FDA Allows their IND for Oraxol, an Oral Form of Paclitaxel that is in Phase II Clinical Trials in Korea, to Begin Clinical Trials in the US
4. ANI Pharmaceuticals, Inc. Announces Date for Second Quarter 2013 Earnings Release
5. QRxPharma Announces Collaboration With Aesica
6. FDAnews Announces Leading the Climb: Seven Essentials of GMP Workshop
7. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
8. HemoShear Announces Advancement of Predictive Drug Safety Systems
9. Cardium Announces Reverse Stock Split
10. STAAR Surgical Announces Second Quarter 2013 Results Release Date And Conference Call And Webcast
11. RXi Pharmaceuticals Announces CEO Interview
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017 Medtec Europe will ... than 600 exhibitors from 70 countries the opportunity ... that will advance the medical technology industry. Taking ... Messe Stuttgart, Stuttgart, Germany , ... showcasing the key trends and insights across the ...
(Date:3/27/2017)... DIEGO and VANCOUVER, British Columbia, March 27, 2017 ... ) (the "Company" or "Sophiris"), a clinical late-stage ... of patients with urological diseases, today reported fourth ... key corporate highlights. Key Corporate ... Clinical Development for Localized Prostate Cancer. During 2016, ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD is pleased to announce it ... for trading on the TSX Venture Exchange.  ... follows a year of significant achievements for Invictus-MD. Some ... test crops at AB Laboratories Inc. ("AB Labs"), a ...
Breaking Medicine Technology:
(Date:3/28/2017)... Switzerland (PRWEB) , ... March 28, 2017 , ... ... for laboratory instruments are critical to ensuring high-quality results and maintaining GMP and ... Qualification of Laboratory Instruments in accordance with GMP requirements " these requirements are ...
(Date:3/28/2017)... Billerica, MA (PRWEB) , ... March 28, 2017 ... ... instrument for direct measurement of corrosive ions found in power plant water and ... plant components such as turbines and boilers, leading to extensive maintenance and unplanned ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Silicon Valley Hair Institute, ... announce a new blog post about women’s hair loss. Although hair transplant procedures can ... as they age. Menopause or genetics can be two reasons a woman may see ...
(Date:3/28/2017)... ... March 28, 2017 , ... Bacteria and fungi are probably not the first ingredients that ... fact, including the right microorganisms in your diet can actually improve health outcomes. And the ... This is the topic of a new peer-reviewed paper led by Maria ...
Breaking Medicine News(10 mins):